Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Assessment of the newborn prenatally exposed to drugs: The history.

Kaltenbach K.

Semin Fetal Neonatal Med. 2019 Apr;24(2):111-114. doi: 10.1016/j.siny.2019.01.008. Epub 2019 Feb 4. Review.

PMID:
30744981
2.

Prenatal Opioid Exposure, Neonatal Abstinence Syndrome/Neonatal Opioid Withdrawal Syndrome, and Later Child Development Research: Shortcomings and Solutions.

Jones HE, Kaltenbach K, Benjamin T, Wachman EM, O'Grady KE.

J Addict Med. 2019 Mar/Apr;13(2):90-92. doi: 10.1097/ADM.0000000000000463.

PMID:
30334926
3.

Reconsidering retrospective review of neurodevelopmental outcomes in infants treated for neonatal abstinence syndrome.

Jones HE, O'Grady KE, Kaltenbach K.

J Perinatol. 2018 Sep;38(9):1280-1281. doi: 10.1038/s41372-018-0174-z. Epub 2018 Jul 30. No abstract available.

PMID:
30061590
4.

Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes.

Kaltenbach K, O'Grady KE, Heil SH, Salisbury AL, Coyle MG, Fischer G, Martin PR, Stine S, Jones HE.

Drug Alcohol Depend. 2018 Apr 1;185:40-49. doi: 10.1016/j.drugalcdep.2017.11.030. Epub 2018 Feb 1.

5.

Impact of Mindfulness-Based Parenting on Women in Treatment for Opioid Use Disorder.

Gannon M, Mackenzie M, Kaltenbach K, Abatemarco D.

J Addict Med. 2017 Sep/Oct;11(5):368-376. doi: 10.1097/ADM.0000000000000336.

PMID:
28746242
6.

Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome.

Kraft WK, Adeniyi-Jones SC, Chervoneva I, Greenspan JS, Abatemarco D, Kaltenbach K, Ehrlich ME.

N Engl J Med. 2017 Jun 15;376(24):2341-2348. doi: 10.1056/NEJMoa1614835. Epub 2017 May 4.

7.

Reducing Stress Among Mothers in Drug Treatment: A Description of a Mindfulness Based Parenting Intervention.

Short VL, Gannon M, Weingarten W, Kaltenbach K, LaNoue M, Abatemarco DJ.

Matern Child Health J. 2017 Jun;21(6):1377-1386. doi: 10.1007/s10995-016-2244-1.

PMID:
28078528
8.

Neonatal Abstinence Syndrome: Presentation and Treatment Considerations.

Jones HE, Kaltenbach K, Johnson E, Seashore C, Freeman E, Malloy E.

J Addict Med. 2016 Jul-Aug;10(4):224-8. doi: 10.1097/ADM.0000000000000222.

PMID:
27244045
9.

Neonatal Abstinence Syndrome: Presentation and Treatment Considerations.

Kaltenbach K, Jones HE.

J Addict Med. 2016 Jul-Aug;10(4):217-23. doi: 10.1097/ADM.0000000000000207. Review.

PMID:
26974659
10.

Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study.

Desai RJ, Huybrechts KF, Hernandez-Diaz S, Mogun H, Patorno E, Kaltenbach K, Kerzner LS, Bateman BT.

BMJ. 2015 May 14;350:h2102. doi: 10.1136/bmj.h2102.

11.

Do maternal opioids reduce neonatal regional brain volumes? A pilot study.

Yuan Q, Rubic M, Seah J, Rae C, Wright IM, Kaltenbach K, Feller JM, Abdel-Latif ME, Chu C, Oei JL; BOB (Brains, Opioids and Babies) Collaborative group.

J Perinatol. 2014 Dec;34(12):909-13. doi: 10.1038/jp.2014.111. Epub 2014 Jun 19.

PMID:
24945162
12.

The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations.

Jones HE, Jansson LM, O'Grady KE, Kaltenbach K.

Neurotoxicol Teratol. 2013 Sep-Oct;39:110-5. doi: 10.1016/j.ntt.2013.05.003.

13.

Nonserious adverse events in randomized trials with opioid-dependent pregnant women: direct versus indirect measurement.

Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR.

Am J Addict. 2012 Nov;21 Suppl 1:S1-4. doi: 10.1111/j.1521-0391.2012.00289.x.

PMID:
23786504
14.

Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention.

Holbrook AM, Jones HE, Heil SH, Martin PR, Stine SM, Fischer G, Coyle MG, Kaltenbach K.

Drug Alcohol Depend. 2013 Sep 1;132(1-2):329-34. doi: 10.1016/j.drugalcdep.2013.02.031. Epub 2013 Mar 21.

15.

Response to Wouldes and Woodward: maternal methadone dose during pregnancy and infant clinical outcome.

O'Grady KE, Jones HE, Jansson LM, Kaltenbach K.

Neurotoxicol Teratol. 2013 Sep-Oct;39:116-8. doi: 10.1016/j.ntt.2013.02.004. Epub 2013 Feb 14. No abstract available.

PMID:
23416427
16.

A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine.

Chisolm MS, Fitzsimons H, Leoutsakos JM, Acquavita SP, Heil SH, Wilson-Murphy M, Tuten M, Kaltenbach K, Martin PR, Winklbaur B, Jansson LM, Jones HE.

Nicotine Tob Res. 2013 Jul;15(7):1297-304. doi: 10.1093/ntr/nts274. Epub 2013 Jan 3.

17.

Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes.

Jones HE, Heil SH, Tuten M, Chisolm MS, Foster JM, O'Grady KE, Kaltenbach K.

Drug Alcohol Depend. 2013 Aug 1;131(3):271-7. doi: 10.1016/j.drugalcdep.2012.11.019. Epub 2012 Dec 29.

18.

Comments on: Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy.

Jones HE, Heil SH, Kaltenbach K, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR.

J Addict Dis. 2012;31(4):321-6; discussion 327-8. doi: 10.1080/10550887.2012.736289. No abstract available.

PMID:
23244549
19.

Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication.

McNicholas LF, Holbrook AM, O'Grady KE, Jones HE, Coyle MG, Martin PR, Heil SH, Stine SM, Kaltenbach K.

Addiction. 2012 Nov;107 Suppl 1:91-7. doi: 10.1111/j.1360-0443.2012.04043.x.

20.

Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine.

Holbrook AM, Baxter JK, Jones HE, Heil SH, Coyle MG, Martin PR, Stine SM, Kaltenbach K.

Addiction. 2012 Nov;107 Suppl 1:83-90. doi: 10.1111/j.1360-0443.2012.04042.x.

21.

Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes.

Benningfield MM, Dietrich MS, Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Fischer G, Martin PR.

Addiction. 2012 Nov;107 Suppl 1:74-82. doi: 10.1111/j.1360-0443.2012.04041.x.

22.

Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates.

Gaalema DE, Scott TL, Heil SH, Coyle MG, Kaltenbach K, Badger GJ, Arria AM, Stine SM, Martin PR, Jones HE.

Addiction. 2012 Nov;107 Suppl 1:53-62. doi: 10.1111/j.1360-0443.2012.04039.x.

23.

Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication.

Kaltenbach K, Holbrook AM, Coyle MG, Heil SH, Salisbury AL, Stine SM, Martin PR, Jones HE.

Addiction. 2012 Nov;107 Suppl 1:45-52. doi: 10.1111/j.1360-0443.2012.04038.x.

24.

Fetal assessment before and after dosing with buprenorphine or methadone.

Salisbury AL, Coyle MG, O'Grady KE, Heil SH, Martin PR, Stine SM, Kaltenbach K, Weninger M, Jones HE.

Addiction. 2012 Nov;107 Suppl 1:36-44. doi: 10.1111/j.1360-0443.2012.04037.x.

25.

Maternal Opioid Treatment: Human Experimental Research (MOTHER)--approach, issues and lessons learned.

Jones HE, Fischer G, Heil SH, Kaltenbach K, Martin PR, Coyle MG, Selby P, Stine SM, O'Grady KE, Arria AM.

Addiction. 2012 Nov;107 Suppl 1:28-35. doi: 10.1111/j.1360-0443.2012.04036.x. Review.

26.

Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.

Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, Coyle MG, Selby P, Stine SM, Fischer G.

Addiction. 2012 Nov;107 Suppl 1:5-27. doi: 10.1111/j.1360-0443.2012.04035.x. Review.

27.

Neonatal abstinence syndrome.

Jones HE, Kaltenbach K.

JAMA. 2012 Aug 22;308(8):762-3; author reply 763. doi: 10.1001/jama.2012.8595. No abstract available.

PMID:
22910747
28.

Cigarette Smoking and Neonatal Outcomes in Depressed and Non-Depressed Opioid-Dependent Agonist-Maintained Pregnant Patients.

Chisolm MS, Acquavita SP, Kaltenbach K, Winklbaur B, Heil SH, Martin PR, Stine SM, Coyle M, Leoutsakos JM, Tuten M, Jansson LM, Backer PM, Jones HE.

Addict Disord Their Treat. 2011 Dec;10(4):180-187.

29.

Co-occurring psychiatric symptoms in opioid-dependent women: the prevalence of antenatal and postnatal depression.

Holbrook A, Kaltenbach K.

Am J Drug Alcohol Abuse. 2012 Nov;38(6):575-9. doi: 10.3109/00952990.2012.696168. Epub 2012 Jul 11.

PMID:
22783870
30.

Methadone and buprenorphine for the management of opioid dependence in pregnancy.

Jones HE, Finnegan LP, Kaltenbach K.

Drugs. 2012 Apr 16;72(6):747-57. doi: 10.2165/11632820-000000000-00000. Review.

PMID:
22512363
31.

Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus?

Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Jansson L, Fischer G.

J Matern Fetal Neonatal Med. 2012 Jul;25(7):1197-201. doi: 10.3109/14767058.2011.653423. Epub 2012 Feb 17. No abstract available.

PMID:
22292518
32.

Effectiveness of a smoking cessation intervention for methadone-maintained women: a comparison of pregnant and parenting women.

Holbrook AM, Kaltenbach KA.

Int J Pediatr. 2011;2011:567056. doi: 10.1155/2011/567056. Epub 2011 Jul 28.

33.

Methadone and perinatal outcomes: another perspective.

Jones HE, Jansson LM, Kaltenbach K.

Am J Obstet Gynecol. 2011 Nov;205(5):e11; author's reply e11-12. doi: 10.1016/j.ajog.2011.06.016. Epub 2011 Jun 15. No abstract available.

PMID:
21784398
34.

Methadone and the causes of maternal and perinatal complications: a response to Pinto et al. "Substance abuse during pregnancy: effect on pregnancy outcomes" [Eur. J. Obstet. Gynecol. Reprod. Biol. 150 (2010) 137-141].

Jones HE, Kaltenbach K, O'Grady KE.

Eur J Obstet Gynecol Reprod Biol. 2011 Sep;158(1):116-7; author reply 117. doi: 10.1016/j.ejogrb.2011.04.006. Epub 2011 May 28. No abstract available.

PMID:
21620557
35.

Neonatal abstinence scores in opioid-exposed and nonexposed neonates: a blinded comparison.

Jones HE, Harrow C, O'Grady KE, Crocetti M, Jansson LM, Kaltenbach K.

J Opioid Manag. 2010 Nov-Dec;6(6):409-13.

PMID:
21269001
36.

Neonatal abstinence syndrome after methadone or buprenorphine exposure.

Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Fischer G.

N Engl J Med. 2010 Dec 9;363(24):2320-31. doi: 10.1056/NEJMoa1005359.

37.

Unintended pregnancy in opioid-abusing women.

Heil SH, Jones HE, Arria A, Kaltenbach K, Coyle M, Fischer G, Stine S, Selby P, Martin PR.

J Subst Abuse Treat. 2011 Mar;40(2):199-202. doi: 10.1016/j.jsat.2010.08.011. Epub 2010 Oct 30.

38.

Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.

Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME.

Addiction. 2011 Mar;106(3):574-80. doi: 10.1111/j.1360-0443.2010.03170.x. Epub 2010 Oct 6.

39.

Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women.

Benningfield MM, Arria AM, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Fischer G, Jones HE, Martin PR.

Am J Addict. 2010 Sep-Oct;19(5):416-21. doi: 10.1111/j.1521-0391.2010.00064.x.

40.

Gender and NAS: does sex matter?

Holbrook A, Kaltenbach K.

Drug Alcohol Depend. 2010 Nov 1;112(1-2):156-9. doi: 10.1016/j.drugalcdep.2010.05.015. Epub 2010 Jun 23.

PMID:
20576365
41.

Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant patient samples.

Jones HE, Heil SH, O'Grady KE, Martin PR, Kaltenbach K, Coyle MG, Stine SM, Selby P, Arria AM, Fischer G.

Am J Drug Alcohol Abuse. 2009;35(5):375-80. doi: 10.1080/00952990903125235.

42.

Clinical characteristics of central European and North American samples of pregnant women screened for opioid agonist treatment.

Unger AS, Martin PR, Kaltenbach K, Stine SM, Heil SH, Jones HE, Arria AM, Coyle MG, Selby P, Fischer G.

Eur Addict Res. 2010;16(2):99-107. doi: 10.1159/000284683. Epub 2010 Feb 17.

43.

Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER study.

Stine SM, Heil SH, Kaltenbach K, Martin PR, Coyle MG, Fischer G, Arria AM, Selby P, Jones HE.

Am J Drug Alcohol Abuse. 2009;35(6):429-33. doi: 10.3109/00952990903374080.

44.

Psychopharmacologic management of opioid-dependent women during pregnancy.

Martin PR, Arria AM, Fischer G, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Selby P, Jones HE.

Am J Addict. 2009 Mar-Apr;18(2):148-56. doi: 10.1080/10550490902772975.

45.
46.

Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial.

Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS, Moody DE, Kaltenbach K, Ehrlich ME.

Pediatrics. 2008 Sep;122(3):e601-7. doi: 10.1542/peds.2008-0571. Epub 2008 Aug 11.

47.

Treatment of opioid-dependent pregnant women: clinical and research issues.

Jones HE, Martin PR, Heil SH, Kaltenbach K, Selby P, Coyle MG, Stine SM, O'Grady KE, Arria AM, Fischer G.

J Subst Abuse Treat. 2008 Oct;35(3):245-59. doi: 10.1016/j.jsat.2007.10.007. Epub 2008 Jan 14. Review.

48.
49.

Maternal methadone dose and neonatal withdrawal.

Berghella V, Lim PJ, Hill MK, Cherpes J, Chennat J, Kaltenbach K.

Am J Obstet Gynecol. 2003 Aug;189(2):312-7.

PMID:
14520184
50.

Multiple predictors of substance-abusing women's treatment and life outcomes: a prospective longitudinal study.

Comfort M, Sockloff A, Loverro J, Kaltenbach K.

Addict Behav. 2003 Mar;28(2):199-224.

PMID:
12573675

Supplemental Content

Loading ...
Support Center